Humacyte, Inc.

HUMA

Humacyte, Inc.

HUMA

Insider Sentiment (TTM):

Last Purchase:2026-05-19Last Sale:2026-05-18Shares Purchased (TTM):67,818Shares Sold (TTM):91,774

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:58,453,619Shares Outstanding:197,846,786Institutional Ownership Pct.:29.54%

Earnings Market Reaction:

Filing Date:2026-08-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	80	49	50	19	38	63	45	21	94	116	80	100
Inventory Net	7	10	14	18	11	8	0	-	-	-	-	-
Accounts Receivable Net Current	0	0	0	1	0	0	0	-	-	-	0	0
Prepaid Expense And Other Assets Current	6	5	3	2	2	2	3	2	3	2	3	3
Short Term Investments	-	-	-	-	-	-	-	-	-	-	0	0
Assets Current	93	64	68	41	52	74	48	23	96	118	83	103
Restricted Cash Noncurrent	0	0	0	0	50	50	50	50	-	-	0	-
Property Plant And Equipment Net	16	17	19	20	21	22	23	24	25	26	27	28
Finance Lease Right Of Use Asset	-	29	29	29	14	15	15	16	17	17	17	18
Other Assets Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Assets	138	111	116	92	139	163	138	115	138	161	128	149
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	5	5	10	7	6	4	7	6	3	6	3
Accrued Liabilities Current	9	9	11	10	9	10	11	11	9	8	9	10
Finance Lease Liability Current	-	2	2	3	3	3	3	3	3	3	3	2
Operating Lease Liability Current	-	-	-	-	-	-	-	0	0	0	0	0
Unsecured Debt Current	-	-	0	3	2	2	1	-	-	-	-	-
Other Liabilities Current	-	-	0	0	0	0	0	-	-	-	0	-
Liabilities Current	15	16	18	26	21	20	20	21	18	14	18	15
Unsecured Long Term Debt	-	-	-	18	66	65	63	62	60	58	39	37
Long Term Debt	36	36	35	-	-	-	0	-	-	-	-	-
Business Combination Contingent Consideration Liab…	9	7	11	22	27	21	71	77	68	43	38	40
Secured Debt Current	-	-	-	-	-	-	-	-	-	-	0	0
Warrants And Rights Outstanding	16	11	19	3	4	3	19	-	-	-	0	-
Finance Lease Liability Noncurrent	-	28	27	27	12	13	14	14	15	16	16	17
Derivative Liabilities Noncurrent	-	-	0	0	3	3	2	3	4	4	3	3
Other Liabilities Noncurrent	2	2	2	1	1	1	1	1	1	1	1	1
Liabilities	107	99	113	96	135	127	191	178	167	135	115	112
Secured Long Term Debt	-	-	-	-	-	-	-	-	-	-	0	0
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	813	756	730	697	689	683	633	601	598	595	551	549
Retained Earnings Accumulated Deficit	-781	-744	-727	-702	-685	-647	-686	-665	-626	-569	-537	-512
Stockholders Equity	31	12	3	-5	4	36	-53	-64	-28	26	14	37
Liabilities And Stockholders Equity	138	111	116	92	139	163	138	115	138	161	128	149
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	20	20	20	20	20	20	20	20	20	20	20	20
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	350	350	350	350	250	250	250	250	250	250	250	250
Common Stock Shares Issued	278	222	193	159	156	155	130	120	119	119	104	103
Shares Outstanding	278	222	193	159	156	155	130	120	119	119	104	103

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	19.47%	-37.17%	-42.21%	-	-	-	-	-	-	-	-	-
2025	49.71%	31.79%	31.79%	-18.05%	20.34%	-4.30%	-1.60%	-22.00%	-20.16%	5.03%	37.57%	56.07%
2024	32.66%	-3.83%	50.55%	-20.75%	-18.20%	-18.95%	-21.80%	-4.84%	-20.24%	-15.54%	48.39%	35.48%
2023	-	-	-	-6.19%	-28.47%	-45.05%	20.36%	28.51%	31.67%	18.97%	103.54%	126.69%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	6.21	3.93	3.69	1.62	2.45	3.68	2.40	1.10	5.41	8.37	4.52	6.79
Quick Ratio	5.37	3.03	2.77	0.80	1.82	3.16	2.25	0.98	5.27	8.20	4.36	6.61
Working Capital	77.84M	47.41M	49.42M	15.77M	30.65M	53.68M	27.91M	2.06M	78.35M	103.84M	64.84M	87.71M
Leverage & Debt
Debt to Equity	3.42	8.51	36.43	-20.26	33.25	3.51	-3.62	-2.80	-5.89	5.17	8.47	3.04
Interest Coverage TTM	-10.80	-10.82	-9.61	-9.88	-10.60	-10.61	-12.33	-13.24	-14.21	-15.50	-15.16	-14.54
Debt Ratio	0.77	0.89	0.97	1.05	0.97	0.78	1.38	1.56	1.20	0.84	0.89	0.75
Efficiency & Turnover
Asset Turnover TTM	0.02	0.01	0.02	0.02	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	62.30	83.46	78.98	250.46	175.81	344.53	-	-	-	-	-	-
Receivables Turnover TTM	5.86	4.37	4.62	1.46	2.08	1.06	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-0.41	-0.49	-0.26	-0.23	-0.38	-0.59	-1.26	-1.28	-1.17	-0.98	-1.07	-0.86
Free Cash Flow Per Share TTM	-0.43	-0.52	-0.67	-0.49	-0.50	-0.77	-0.84	-0.77	-0.69	-0.77	-0.73	-0.73
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-494.58%	-475.05%	-376.05%	-	-	-	-	-	-	-	-	-
Operating Profit Margin TTM	-5,240.78%	-5,649.21%	-5,306.04%	-6,708.40%	-13,598.04%	-21,470.79%	-	-	-	-	-	-
Net Profit Margin TTM	-4,560.82%	-4,840.82%	-2,003.58%	-2,353.21%	-7,171.27%	-15,022.44%	-	-	-	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	159.29%	289.94%	-	-	-	-	-	-	-	-	-	-
Net Income Growth (1Y)	64.91%	25.65%	-72.54%	-75.82%	-58.00%	-26.52%	34.24%	71.01%	57.49%	263.22%	825.83%	-360.31%
EPS Growth (1Y)	9.45%	-16.48%	-79.43%	-81.76%	-67.80%	-39.52%	17.17%	48.15%	36.60%	246.50%	822.53%	-359.27%
Valuation Metrics
P/E TTM	-1.89	-1.23	-3.72	-7.45	-5.54	-2.89	-4.02	-4.25	-4.10	-3.18	-2.65	-3.39
P/B TTM	5.84	10.33	48.89	-57.98	80.17	6.22	-11.36	-10.19	-20.22	12.87	21.68	8.19
P/S TTM	86.12	59.57	74.58	175.34	397.14	433.66	-	-	-	-	-	-
Market Cap	182.66M	120.09M	151.99M	275.47M	324.86M	224.20M	598.32M	649.58M	572.04M	336.65M	293.71M	303.09M
Enterprise Value	138.73M	107.07M	136.59M	306.20M	320.14M	193.21M	583.81M	657.99M	556.07M	297.26M	270.37M	259.48M
Calculated Values
Free Cash Flow TTM	-101.25M	-102.38M	-105.93M	-77.57M	-77.46M	-100.79M	-99.69M	-92.26M	-81.92M	-83.53M	-75.59M	-76.02M
Net Debt	-43.93M	-13.02M	-15.41M	30.73M	-4.72M	-30.99M	-14.51M	8.40M	-15.97M	-39.39M	-23.35M	-43.61M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-19Purchase

Owner: Sebelius, Kathleen

Title: -

Shares: 56,818

Price/Share: $0.88

Value: $49,999.84

Shares Owned: 148,025

Relationship: Director

Ownership: Direct

2026-05-18Sale

Owner: Parikh, Shamik J

Title: Chief Medical Officer

Shares: 45,887

Price/Share: $0.90

Value: $41,298.30

Shares Owned: 272,713

Relationship: Officer

Ownership: Direct

2026-05-18Sale

Owner: Sander, Dale A.

Title: CFO and Chief Corp. Dev. Off

Shares: 45,887

Price/Share: $0.90

Value: $41,298.30

Shares Owned: 267,213

Relationship: Officer

Ownership: Direct

2026-05-18Purchase

Owner: Constantino, Michael T.

Title: -

Shares: 11,000

Price/Share: $0.89

Value: $9,790.00

Shares Owned: 43,950

Relationship: Director

Ownership: Direct

2025-08-20Sale

Owner: Niklason, Laura E

Title: President, CEO and Director

Shares: 591,685

Price/Share: $1.58

Value: $934,862.30

Shares Owned: -

Relationship: Director,Officer

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-19	Sebelius, Kathleen	Director	-	Direct	Purchase	56,818	0.88	$49,999.84	148,025	4
2026-05-18	Parikh, Shamik J	Officer	Chief Medical Officer	Direct	Sale	45,887	0.90	$41,298.30	272,713	4
2026-05-18	Sander, Dale A.	Officer	CFO and Chief Corp. Dev. Off	Direct	Sale	45,887	0.90	$41,298.30	267,213	4
2026-05-18	Constantino, Michael T.	Director	-	Direct	Purchase	11,000	0.89	$9,790.00	43,950	4
2025-08-20	Niklason, Laura E	Director,Officer	President, CEO and Director	Indirect	Sale	591,685	1.58	$934,862.30	0	4
2025-08-20	Dougan, Brady W	Director	-	Indirect	Sale	591,685	1.58	$934,862.30	0	4
2025-04-14	Scheessele, William John	Officer	Chief Commercial Officer	Direct	Purchase	6,493	1.54	$9,999.22	22,018	4
2025-04-10	Parikh, Shamik J	Officer	Chief Medical Officer	Direct	Purchase	7,500	1.55	$11,625.00	7,500	4
2025-04-10	Sander, Dale A.	Officer	CFO and Chief Corp. Deve. Off.	Indirect	Purchase	20,000	1.53	$30,600.00	40,600	4
2025-04-08	Sebelius, Kathleen	Director	-	Direct	Purchase	50,000	1.32	$66,000.00	91,207	4
2025-04-08	Green, Charles Bruce	Director	-	Direct	Purchase	6,000	1.29	$7,740.00	8,400	4
2025-04-07	Constantino, Michael T.	Director	-	Direct	Purchase	16,000	1.26	$20,160.00	32,950	4
2024-12-04	Constantino, Michael T.	Director	-	Direct	Purchase	4,600	4.39	$20,194.00	16,950	4
2024-11-20	Niklason, Laura E	Director,Officer	President, CEO and Director	Indirect	Sale	261,369	4.40	$1,150,023.60	1,730,884	4
2024-11-20	Dougan, Brady W	Director	-	Indirect	Sale	261,369	4.40	$1,150,023.60	1,730,884	4
2024-11-19	Dougan, Brady W	Director	-	Indirect	Purchase	1,797	4.44	$7,978.68	243,851	4
2024-11-19	Niklason, Laura E	Director,Officer	President, CEO and Director	Direct	Purchase	1,797	4.44	$7,978.68	243,851	4
2024-09-10	Sebelius, Kathleen	Director	-	Direct	Sale	5,182	5.40	$27,982.80	40,276	4
2024-09-10	Niklason, Laura E	Director,Officer	President, CEO and Director	Indirect	Sale	288,674	5.23	$1,509,765.02	3,230,884	4
2024-09-10	Dougan, Brady W	Director	-	Indirect	Sale	288,674	5.23	$1,509,765.02	3,230,884	4
2024-08-29	Dougan, Brady W	Director	-	Indirect	Sale	352,112	6.35	$2,235,911.20	3,677,262	4
2024-08-29	Niklason, Laura E	Director,Officer	President, CEO and Director	Direct	Purchase	1,222	6.55	$8,004.10	242,054	4
2024-08-29	Dougan, Brady W	Director	-	Indirect	Purchase	1,222	6.55	$8,004.10	242,054	4
2024-08-29	Niklason, Laura E	Director,Officer	President, CEO and Director	Indirect	Sale	352,112	6.35	$2,235,911.20	3,677,262	4
2024-08-27	Sander, Dale A.	Officer	CFO and Chief Corp. Deve. Off.	Direct	Sale	39,389	6.68	$263,118.52	2,000	4
2024-08-15	Constantino, Michael T.	Director	-	Direct	Purchase	3,100	6.29	$19,499.00	12,350	4
2024-06-12	Niklason, Laura E	Director,Officer	President, CEO and Director	Indirect	Sale	271,518	7.30	$1,982,081.40	4,559,140	4
2024-06-12	Dougan, Brady W	Director	-	Indirect	Sale	271,518	7.30	$1,982,081.40	4,559,140	4
2024-06-04	Dougan, Brady W	Director	-	Indirect	Sale	1,852	7.28	$13,482.56	5,189,288	4
2024-06-04	Niklason, Laura E	Director,Officer	President, CEO and Director	Direct	Purchase	2,362	6.35	$14,998.70	240,832	4
2024-06-04	Dougan, Brady W	Director	-	Indirect	Purchase	2,362	6.35	$14,998.70	240,832	4
2024-06-04	Niklason, Laura E	Director,Officer	President, CEO and Director	Indirect	Sale	1,852	7.28	$13,482.56	5,189,288	4
2024-06-03	Niklason, Laura E	Director,Officer	President, CEO and Director	Direct	Purchase	2,050	7.37	$15,108.50	238,470	4
2024-06-03	Dougan, Brady W	Director	-	Indirect	Purchase	2,050	7.37	$15,108.50	238,470	4
2024-05-31	Prichard, Heather Ledbett…	Officer	Chief Operating Officer	Direct	Sale	2,625	9.41	$24,701.25	0	4
2024-05-20	Wallace, Max N.	Director	-	Indirect	Purchase	8,005	6.25	$50,031.25	4,015	4
2024-05-15	Binder, Gordon M	Director	-	Direct	Purchase	50,000	6.78	$339,000.00	160,000	4
2023-09-14	Niklason, Laura E	Director,Officer	President, CEO and Director	Indirect	Sale	2,000,000	2.78	$5,560,000.00	6,191,140	4
2023-09-14	Dougan, Brady W	Director	-	Indirect	Sale	2,000,000	2.78	$5,560,000.00	6,191,140	4
2023-08-21	Ayabudge, Llc	TenPercentOwner	-	Direct	Sale	602,443	3.39	$2,042,281.77	8,191,140	4
2023-08-21	Dougan, Brady W	Director	-	Indirect	Sale	602,443	3.39	$2,042,281.77	8,191,140	4
2023-08-21	Niklason, Laura E	Director,Officer	President, CEO and Director	Indirect	Sale	602,443	3.39	$2,042,281.77	8,191,140	4
2023-06-15	Niklason, Laura E	Director,Officer,TenPercentOwner	President, CEO and Director	Indirect	Sale	500,000	3.12	$1,560,000.00	9,990,736	4
2023-06-15	Ayabudge, Llc	TenPercentOwner	-	Direct	Sale	500,000	3.12	$1,560,000.00	9,990,736	4
2023-06-15	Dougan, Brady W	Director,TenPercentOwner	-	Indirect	Sale	500,000	3.12	$1,560,000.00	9,990,736	4
2023-06-13	Ayabudge, Llc	TenPercentOwner	-	Direct	Sale	4,875,000	2.60	$12,675,000.00	10,490,736	4
2023-06-13	Niklason, Laura E	Director,Officer,TenPercentOwner	President, CEO and Director	Indirect	Sale	4,875,000	2.60	$12,675,000.00	10,490,736	4
2023-06-13	Dougan, Brady W	Director,TenPercentOwner	-	Indirect	Sale	4,875,000	2.60	$12,675,000.00	10,490,736	4
2023-05-25	Dougan, Brady W	Director,TenPercentOwner	-	Indirect	Sale	2,625,000	2.75	$7,218,750.00	15,365,736	4
2023-05-25	Niklason, Laura E	Director,Officer,TenPercentOwner	President, CEO and Director	Indirect	Sale	2,625,000	2.75	$7,218,750.00	15,365,736	4
2023-05-25	Ayabudge, Llc	TenPercentOwner	-	Direct	Sale	2,625,000	2.75	$7,218,750.00	15,365,736	4
2023-05-25	Prichard, Heather Ledbett…	Officer	Chief Operating Officer	Direct	Sale	9,613	3.83	$36,817.79	64,566	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

29.54%

Inst. Shares: 58,453,619

Shares Outstanding: 197,846,786

2025-12-31

34.59%

Inst. Shares: 54,706,738

Shares Outstanding: 158,160,468

2025-09-30

28.83%

Inst. Shares: 45,637,191

Shares Outstanding: 158,313,290

2025-06-30

35.38%

Inst. Shares: 54,986,917

Shares Outstanding: 155,437,281

2025-03-31

45.40%

Inst. Shares: 59,699,234

Shares Outstanding: 131,496,877

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	58,453,619	197,846,786	29.54%
2025-12-31	54,706,738	158,160,468	34.59%
2025-09-30	45,637,191	158,313,290	28.83%
2025-06-30	54,986,917	155,437,281	35.38%
2025-03-31	59,699,234	131,496,877	45.40%
2024-12-31	40,938,827	118,479,097	34.55%
2024-09-30	34,878,873	119,408,565	29.21%
2024-06-30	30,563,127	119,174,681	25.65%
2024-03-31	22,735,611	108,246,008	21.00%
2023-12-31	17,062,419	103,420,238	16.50%
2023-09-30	16,040,113	103,444,246	15.51%
2023-06-30	14,191,586	103,361,501	13.73%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Humacyte, Inc. (HUMA) — SEC Financial Statements & Analysis

Humacyte, Inc. (HUMA) is a biological products, (no diagnostic substances) company, incorporated in DE. Humacyte, Inc. trades on Nasdaq as: HUMA, HUMAW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Humacyte, Inc. reported a 159.29% year-over-year revenue growth, a Gross Profit Margin of -494.58% (TTM), a Debt-to-Equity ratio of 3.42x, a Price-to-Sales (P/S) ratio of 86.12x (TTM), a Price-to-Book (P/B) ratio of 5.84x (TTM), at a market cap of $182.66M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 159.29%
Gross Profit Margin TTM: -494.58%
Debt To Equity: 3.42x
P/S TTM: 86.12x
P/B TTM: 5.84x
Market Cap: $182.66M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Humacyte, Inc. in?

Humacyte, Inc. (HUMA) operates in the Biological Products, (No Diagnostic Substances) industry.

What is HUMA's market cap?

Humacyte, Inc. (HUMA) has a market capitalization of $182.66M as of 2026-06-30.

What exchange does HUMA trade on?

Humacyte, Inc. (HUMA) trades on the Nasdaq.

Where is Humacyte, Inc. incorporated?

Humacyte, Inc. is incorporated in DE.

Humacyte, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Humacyte, Inc. (HUMA) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

Humacyte, Inc. (HUMA) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.